Aditxt, Inc.
ADTX
OTC·Healthcare·Biotechnology·Mkt cap $7.0M
$0.00
▼ -17.95%
P/E
—
Mkt Cap
$7.0M
52-Wk Range
$0.00–$18,721
52-Week Range
$0.00 - $18,720.94
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 100.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary immune mapping and reprogramming technology platform
- Strategic partnerships with Stanford University and Loma Linda University
- First-mover advantage in personalized immune profiling diagnostics
- Patent-protected nucleic acid-based therapeutic approach
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion of AditxtScore adoption among healthcare providers and consumers
Value
Valuation data unavailable
Momentum
Falling
-21.2% over 3m
Quality
Thin
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying ADTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Dec 2, 2026
Most recent quarter reported revenue of $12.2K. Reported EPS of -$790.49. Gross margin 23.6%.
Reported EPS · last 4Q
Q1 26
-$790.49
Q4 25
-$148.00
Q3 25
-$548.78
Q2 25
-$3.45
Revenue trend · last 8Q
—
—
—
—
-98%
-89%
-87%
+1094%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$44.3K
$6.9K
$3.2K
$1.0K
$1.0K
$748
$425
$12.2K
Margins · last 8Q
Gross
23.6%
Profit
-131159.8%
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How ADTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related